Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1 12Phase 1/2 5Phase 3 3Phase NA 2Phase EARLY_PHASE1 2

Status

Completed 25Unknown 6Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 2Neoplasms 1Carcinoma 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Lapatinib × Clear all
NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Novartis

Phase 3 Terminated
63 enrolled 22 charts
Breast

Breast Neoplasms

NCT00508274 2021-09-21

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Novartis

Phase 3 Terminated
52 enrolled 12 charts
Breast

Breast Neoplasms

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Novartis

Phase 3 Terminated
37 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡